Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
AssigneeAradigm Corporation
InventorsGul Balwani, Brooks Boyd, John Whatley
Life of this patent
Estimating the term…
Abstract
Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon, and proteins in general, for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.
Claims21
1-78. (canceled)
A stable, aqueous formulation of a biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising:
- about 0.5 to about 12.0 mg of biologically active human protein per mL of the formulation;
- about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation;
- about 0.45 to about 0.60 mg Na2HPO4.7H2O per mL of the formulation;
- at least about 0.5 mg Polysorbate 20 per mL of the formulation;
- and water for injection as the solvent;
- wherein the amounts of Na2HPO4.7H2O and Na2HPO4.7H2O are adjusted to bring the pH of the formulation to about 7.0 to 8.0.
A stable, aqueous formulation of alpha interferon for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising:
- about 0.5 to about 12.0 mg alpha interferon per mL of the formulation;
- a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0;
- a poly(oxy-1,2-ethanediyl) derivative;
- and water.
A stable, aqueous formulation of alpha interferon for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising:
- about 5.5 to about 5.6 mg alpha-2b interferon per mL of the formulation;
- about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation;
- about 0.45 to about 0.60 mg Na2HPO4.7H2O per mL of the formulation;
- at least about 0.5 mg Polysorbate 20 per mL of the formulation;
- and water for injection as the solvent;
- wherein the amounts of Na2HPO4.7H2O and Na2HPO4.7H2O are adjusted to bring the pH of the formulation to about 7.4 to 7.6.
An article of manufacture comprising:
- a sterilized filling vessel;
- and
- a stable, aqueous formulation of biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising about 0.5 to about 12.0 mg of biologically active human protein per mL of the formulation;
- a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0;
- a sorbitan, monododecanoate;
- and water;
- wherein said protein is alpha-2b interferon;
- wherein said sterilized filling vessel comprises a single dose container which is adapted to be sealed after receiving said formulation, wherein said single dose container is a blister pack and wherein about 45 microliters to about 2.5 microliters of said formulation are contained by said blister pack.
An article of manufacture comprising:
- a sealed, sterile blister pack containing a stable, aqueous formulation of biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising about 0.5 to about 12.0 mg biologically active human protein per mL of the formulation;
- a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0;
- a poly(oxy-1,2-ethanediyl) derivative;
- and water.
A method of providing a biologically active human protein in a form and concentration able to be systemically delivered to a patient via the lungs, said method comprising the steps of:
- providing a biologically active human protein solution having a known, selected biological activity, and containing a buffering system and a stabilizing agent;
- and aerosolizing the solution to form an aerosol of aqueous droplets, wherein the aerosol has a fine particle fraction of at least about 50 percent.
An aerosolized stable, aqueous formulation of a recombinantly produced, biologically active, human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising:
- about 4.0 to about 12.0 mg recombinantly produced, biologically active, human protein per mL of the formulation;
- about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation;
- about 0.45 to about 0.60 mg NaH2PO4.2H2O per mL of the formulation;
- at least about 0.5 mg Polysorbate 20 per mL of the formulation;
- and
- water for injection as the solvent;
- wherein the amounts of Na2HPO4.7H2O and NaH2PO4.2H2O are adjusted to bring the pH of the formulation to about 7.0 to 8.0 and the aerosol is comprised of particles have an aerodynamic diameter in a range of from about 1 micron to about 12 microns.
Dependencies are inferred from the claim text.